Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States subpoena J&J information

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson reveals multiple state attorneys general are seeking documents related to the April McNeil Consumer Healthcare recalls of Children's Tylenol and other pediatric liquid OTCs. Company officials said during a recent earnings call that the U.S. Attorney's Office for the Eastern District of Pennsylvania issued a grand jury subpoena related to the McNeil recalls (1"The Tan Sheet" July 26, 2010). The company said Aug. 11 in its fiscal 2010 second-quarter Security Exchange Commission filing that it has received civil investigative demands from other states as well. The firm does not expect the legal proceedings to adversely impact its financial condition

You may also be interested in...

McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena

Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts